Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

NCT05203705 ↗

Phase 2 Terminated 64 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multi-center, randomized, open-label, double-blind, positive-controlled phase II clinical study evaluating the efficacy and safety of different doses of SHR2285 tablets vs. enoxaparin for the prevention of postoperative venous thromboembolism in patients undergoing elective unilateral total knee arthroplasty.

Timeline

Start: 2022-03-07
Primary completion: 2023-03-14
Completion: 2023-03-14

Outcome

Outcome not reported

Stopped (Business): “Adjustment of the sponsor's R\&D strategy”

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Enoxaparin sodium	Other / unclassified	—	—
Subject	SHR2285	Small molecule	—	—

Indications

No indication recorded.